The dimensions of growth and innovation are evidenced through investments totaling R $ 650 million. Photo: Prati-Donaduzzi Press.
The health crisis that the world is facing has shown an atypical scenario and full of challenges. Although the effects of COVID-19 affect the economic sectors, Prati-Donaduzzi pharmaceutical industry seeks alternatives to face the moment and maintains its strategic planning.
The industry has a series of investments aimed at increasing production capacity and its product portfolio. Among the actions is the modernization of the industrial park, with the acquisition of new high-tech equipment, the construction of the new Distribution Center and the industry also plans to build a new manufacturing facility.
The dimensions of growth and innovation are evidenced through investments totaling R$ 650 million, which were announced and confirmed at the beginning of the year. “Even with the pandemic, we continue to believe in the potential of the country and the pharmaceutical market. We have not reduced our planned investments”, says Prati-Donaduzzi CEO, Eder Fernando Maffissoni.
Recently, 17 containers of state-of-the-art equipment of German origin arrived at the pharmaceutical company. For the next few days, it is expected to receive a complete line of fully automated and high performance Italian technology packaging.
This equipment is part of the first stage of the project to increase production capacity and modernize the current plants. “We are working at a fast pace, every shift, 24 hours. We have to expand. In this first moment alone, we invested R $ 40 million in equipment”, stresses the CEO.
This equipment is part of the first stage of the project to increase production capacity and modernize the current plants. “We are working at a fast pace, 24/7. We have to expand. At this moment, we invested R$ 40 million in equipment”, says the CEO.
Prati-Donaduzzi is a benchmark in terms of medicines in Brazil. Photo: Prati-Donaduzzi Press.
Construction at full speed
In order to follow this growth, Prati-Donaduzzi also invests in a new Distribution Center, which is located in the complex of the Biosciences Scientific and Technological Park (Biopark), and advances in the construction. The new structure will be used to store the final products destined for the branches and Distribution Centers spread throughout Brazil. The construction is expected to be completed by the end of this year.
"The structure will have more than 14 thousand square meters, will house approximately 17,500 pallet positions and will have about 130 employees", explains Maffissoni.
Prati-Donaduzzi is a benchmark in terms of medicines in Brazil for its excellence in production, product quality and, mainly, for its investments in people. Even with the pandemic, the industry continues with the selection processes, respecting all the safety standards of the health agencies.
“Currently, Prati-Donaduzzi Group generates more than 4,400 direct jobs and new jobs are foreseen due to our growing investments and growth”, he prospects.
Health and economic instability also has an impact on the pharmaceutical industry. However, being aware of its important role in society at a time when medicines are essential, Prati-Donaduzzi has adopted measures to maintain production and especially the safety and care of its employees.
“Since January, we have adopted prevention protocols and have moved forward following all the measures recommended by health agencies. Everything is meant to ensure even more health for those who make from their work the mission of producing quality drugs”, concludes the CEO.